B · Normal
On October 22, the Phase III trial of Lutikizumab, a biologic agent under development by AbbVie, reached its primary endpoint.
Related telegraphs
[Berkshire Hathaway’s stock price rose 1.1% and continued to set a new record hi
10-22 21:45
On October 22, U.S. cryptocurrency concept stocks fell, with Coinbase falling by
10-22 21:40
On October 22, Meta’s early trading decline expanded to 6%, and its market value
10-22 21:37
On October 22, Lockheed Martin's stock price rose 8.6% after the company raised
10-22 21:37
On October 22, SpaceX’s stock price fell 5.1% in early trading, and its market v
10-22 21:34
On October 22nd, IBM's stock rose by more than 1% after falling by more than 4%.
10-22 21:32
Comments